Cargando…
Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study)
The use of noninsulin antihyperglycaemic drugs in the hospital setting has not yet been fully described. This observational study compared the efficacy and safety of the standard basal-bolus insulin regimen versus a dipeptidyl peptidase-4 inhibitor (linagliptin) plus basal insulin in medicine depart...
Autores principales: | Pérez-Belmonte, Luis M., Gómez-Doblas, Juan J., Millán-Gómez, Mercedes, López-Carmona, María D., Guijarro-Merino, Ricardo, Carrasco-Chinchilla, Fernando, de Teresa-Galván, Eduardo, Jiménez-Navarro, Manuel, Bernal-López, M. Rosa, Gómez-Huelgas, Ricardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162816/ https://www.ncbi.nlm.nih.gov/pubmed/30208631 http://dx.doi.org/10.3390/jcm7090271 |
Ejemplares similares
-
Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2022) -
Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021) -
Trends in Diabetes-Related Potentially Preventable Hospitalizations in Adult Population in Spain, 1997–2015: A Nation-Wide Population-Based Study
por: Gómez-Huelgas, Ricardo, et al.
Publicado: (2019) -
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
por: Bernardo, Miquel, et al.
Publicado: (2021) -
De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)